Sign Up Today and Learn More About Gilgamesh Pharmaceuticals Stock
Invest in or calculate the value of your shares in Gilgamesh Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Gilgamesh Pharmaceuticals Stock (GIPH)
Gilgamesh Pharmaceuticals provides medicines for psychedelic, novel psychotropic drugs, depression, anxiety, and stress-related disorders.
About Gilgamesh Pharmaceuticals Stock
Founded
2019
Headquarters
New York, NY, US
Industries
Science and Engineering, Health Care, Biotechnology
Gilgamesh Pharmaceuticals Press Mentions
Stay in the know about the latest news on Gilgamesh Pharmaceuticals
Crystalline salts of n-ethyl-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine
patents • Apr 02, 2025
Crystalline hydrochloride and fumarate salts of n-ethyl-2- (5-fluoro-1h-indol-3 …
patents • Apr 02, 2025
Novel ergolines and methods of treating mood disorders
patents • Apr 02, 2025
Tryptamines and methods of treating mood disorders
patents • Apr 02, 2025
Arylcyclohexylamine derivatives and their use in the treatment of psychiatric …
patents • Apr 02, 2025
Gilgamesh Pharmaceuticals Management
Leadership team at Gilgamesh Pharmaceuticals
Board Member
Amy Kruse
Discovery Chemist & Co-Founder
Mike Cunningham
Join now and verify your accreditation status to gain access to:
- Gilgamesh Pharmaceuticals Current Valuation
- Gilgamesh Pharmaceuticals Stock Price
- Gilgamesh Pharmaceuticals Management
- Available deals in Gilgamesh Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Gilgamesh Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Gilgamesh Pharmaceuticals Revenue and Financials
- Gilgamesh Pharmaceuticals Highlights
- Gilgamesh Pharmaceuticals Business Model
- Gilgamesh Pharmaceuticals Risk Factors
- Gilgamesh Pharmaceuticals Research Report from SACRA Research
Trading Gilgamesh Pharmaceuticals Stock
How to invest in Gilgamesh Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Gilgamesh Pharmaceuticals through EquityZen funds. These investments are made available by existing Gilgamesh Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Gilgamesh Pharmaceuticals stock?
Shareholders can sell their Gilgamesh Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
